Guardant Health

216 articles about Guardant Health

• Guardant Health to Participate in Upcoming June 2023 Investor Conferences

  5/26/2023

  Guardant Health, Inc., a leading precision oncology company, announced the company will be participating in the following investor conferences.

• Guardant Health Announces Pricing of Upsized Public Offering of Common Stock - May 23, 2023

  5/23/2023

  Guardant Health, Inc., a leading precision oncology company, announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions.

• Guardant Health Announces Proposed Public Offering of Common Stock - May 22, 2023

  5/22/2023

  Guardant Health, Inc., a leading precision oncology company, announced that it has commenced an underwritten public offering of $250.0 million of its common stock.

• Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling

  5/17/2023

  Guardant Health, Inc., a leading precision oncology company, announced that it has received new commercial health plan coverage for the Guardant360 liquid biopsy test from Anthem Blue Cross and Blue Shield, Aetna and Humana.

• Guardant Health Reports First Quarter 2023 Financial Results

  5/9/2023

  Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, reported financial results for the quarter ended March 31, 2023.

• Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test

  5/9/2023

  Guardant Health, Inc. (Nasdaq: GH) today presented additional data from the ECLIPSE study at 2023 Digestive Disease Week (DDW) titled, “Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population” (Abstract #913e) showcasing the performance of its blood-based technology to accurately detect early-stage colorectal cancer (CRC).

• Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference

  4/27/2023

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada.

• Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response

  4/25/2023

  Guardant Health, Inc. and the Parker Institute for Cancer Immunotherapy (PICI) today announced a research collaboration agreement to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across more than 14 different types of cancer.

• Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer

  4/21/2023

  Guardant Health, Inc. is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC).

• Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023

  4/19/2023

  Guardant Health, Inc., a leading precision oncology company, announced it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023.

• Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy

  4/18/2023

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for the Guardant360 Response test.

• Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting

  4/11/2023

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

• Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence

  3/21/2023

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to evaluate patient compliance with a blood-based test for colorectal cancer (CRC) screening.

• Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test

  3/10/2023

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield™, Guardant Health’s blood test to screen for colorectal cancer (CRC).

• Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook

  2/23/2023

  Guardant Health, Inc. today reported financial results for the quarter and full year ended December 31, 2022.

• Guardant Health to Participate in Upcoming March 2023 Investor Conferences

  2/17/2023

  Guardant Health, Inc., a leading precision oncology company, announced the company will be participating in the following investor conferences.

• Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer

  2/15/2023

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the initiation of a new study to examine patient preference for Shield, Guardant Health’s blood test to screen for colorectal cancer (CRC), and if having the option of a blood test improves patient adherence to screening.

• Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer

  2/8/2023

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that UnitedHealthcare (UHC) now covers the Guardant360® CDx liquid biopsy test for patients enrolled in its commercial policies for all FDA-approved companion diagnostic indications.

• Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 Tissue

  2/2/2023

  Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 ® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.

• Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

  2/1/2023

  Guardant Health, Inc., a leading precision oncology company, announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023.